Global Dementia Drugs Market to Reach USD 26.75 Billion by 2034 | CAGR of 6.20% Driven by Aging Population & Innovation

The global dementia drugs market, valued at USD 14.66 billion in 2024, is anticipated to reach USD 26.75 billion by 2034, expanding at a CAGR of 6.20%. This growth is fueled by the rising global incidence of neurodegenerative disorders, especially Alzheimer's disease. Key market drivers include an aging population, improved diagnostics, and growing awareness of cognitive health. Advances in disease-modifying therapies, AI-based tools, and personalized medicine are revolutionizing dementia treatment. North America leads in market share, while the Asia Pacific region shows the fastest growth. Ongoing R&D investments, public-private collaborations, and recent regulatory updates are shaping a more responsive and innovative market landscape. Major players include Biogen, Eisai, Johnson & Johnson, and Eli Lilly, each contributing to groundbreaking developments in dementia care.